ReviewHuman vaccines & immunotherapeutics2026
Harnessing conserved epitopes and multivalent antigen strategies for vaccine design: Lessons learned and opportunities.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccination remains a cornerstone of global disease prevention, yet outcomes differ markedly across pathogens. For antigenically stable viruses such as hepatitis B virus (HBV), vaccines have achieved durable, cross-genotype protection and have substantially reduced disease burden worldwide. In contrast, extensive antigenic diversity in other pathogens enables immune escape, narrows protective responses, and complicates the development of broadly effective vaccines. Lessons from HBV suggest that targeting conserved, immunodominant antigens can underpin durable immunity. It has, however, proven difficult to translate this to highly variable pathogens. Conserved epitopes are often structurally masked or immunologically subdominant, limiting their ability to elicit robust protective responses. In addition, determinants that govern whether conserved epitope responses translate into durable protection remain poorly understood. This narrative review examines current progress, challenges, and opportunities and highlights how conserved epitopes and multivalent vaccine strategies can inform the next generation of broadly protective vaccines against antigenically diverse pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.